Mindset Pharma shares positive preclinical results on its two sets of psychedelic drug families

Name: Mindset Pharma shares positive preclinical results on its two sets of psychedelic drug families
Uploaded: 2021-08-10T09:04:00Z
Description: Mindset Pharma shares positive preclinical results on its two sets of psychedelic drug families

Proactive Published 10/08/2021

Share X in f @

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF). (CSE: MSET) (OTCQB: MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo talk to Proactive on results from the Toronto, Canada-based psychedelic medicines-focused group's psilocybin/psilocin analogs, and DMT/5-MeO-DMT analogs.

Lanthier and Araujo say both have demonstrated superior efficacy, safety, and shorter duration of action in head-to-head preclinical comparisons with their reference drugs.